Can biomedical tech transfer create both goodwill and good wealth? The case for a global fair profit/for profit model

摘要

Proposed here as a technology transfer practice, we highlight the adoption of a fair profit/for profit model as a means for sustainable biomedical commercialisation. This model de-emphasises short-term, profit maximisation (full-profit) strategies and highlights the tech transfer advantages of niche markets and localised manufacturing, coupled with proven best practices of medical specialties and focused on global market needs. This model recognises, but is not driven by, local regulatory barriers and minimises or eliminates the development and marketing costs traditionally associated with new medical products in industrialised nations. Such a model can be sustainable and profitable, when adopted as part of a global, controlled-growth commercialisation strategy.